The risk of cancer in people with diabetes and chronic kidney disease

Germaine Wong, Sophia Zoungas, Serigne Lo, John Chalmers, Alan Cass, Bruce Neal, Mark Woodward, Vlado Perkovic, Paul Glasziou, Bryan Williams, Kirsten Howard, Jeremy R. Chapman, Jonathan C. Craig

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).

Original languageEnglish
Pages (from-to)3337-3344
Number of pages8
JournalNephrology Dialysis Transplantation
Volume27
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Chronic Renal Insufficiency
Neoplasms
perindopril drug combination indapamide
Glomerular Filtration Rate
Type 2 Diabetes Mellitus
Gliclazide
Vascular Diseases
Proportional Hazards Models
Confidence Intervals
Kidney

Cite this

Wong, G., Zoungas, S., Lo, S., Chalmers, J., Cass, A., Neal, B., ... Craig, J. C. (2012). The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 27(8), 3337-3344. https://doi.org/10.1093/ndt/gfs022
Wong, Germaine ; Zoungas, Sophia ; Lo, Serigne ; Chalmers, John ; Cass, Alan ; Neal, Bruce ; Woodward, Mark ; Perkovic, Vlado ; Glasziou, Paul ; Williams, Bryan ; Howard, Kirsten ; Chapman, Jeremy R. ; Craig, Jonathan C. / The risk of cancer in people with diabetes and chronic kidney disease. In: Nephrology Dialysis Transplantation. 2012 ; Vol. 27, No. 8. pp. 3337-3344.
@article{db6a5d797279439c989be64e8bbcfefd,
title = "The risk of cancer in people with diabetes and chronic kidney disease",
abstract = "Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).",
author = "Germaine Wong and Sophia Zoungas and Serigne Lo and John Chalmers and Alan Cass and Bruce Neal and Mark Woodward and Vlado Perkovic and Paul Glasziou and Bryan Williams and Kirsten Howard and Chapman, {Jeremy R.} and Craig, {Jonathan C.}",
year = "2012",
month = "8",
doi = "10.1093/ndt/gfs022",
language = "English",
volume = "27",
pages = "3337--3344",
journal = "Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress",
issn = "0931-0509",
publisher = "OXFORD UNIV PRESS",
number = "8",

}

Wong, G, Zoungas, S, Lo, S, Chalmers, J, Cass, A, Neal, B, Woodward, M, Perkovic, V, Glasziou, P, Williams, B, Howard, K, Chapman, JR & Craig, JC 2012, 'The risk of cancer in people with diabetes and chronic kidney disease' Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3337-3344. https://doi.org/10.1093/ndt/gfs022

The risk of cancer in people with diabetes and chronic kidney disease. / Wong, Germaine; Zoungas, Sophia; Lo, Serigne; Chalmers, John; Cass, Alan; Neal, Bruce; Woodward, Mark; Perkovic, Vlado; Glasziou, Paul; Williams, Bryan; Howard, Kirsten; Chapman, Jeremy R.; Craig, Jonathan C.

In: Nephrology Dialysis Transplantation, Vol. 27, No. 8, 08.2012, p. 3337-3344.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The risk of cancer in people with diabetes and chronic kidney disease

AU - Wong, Germaine

AU - Zoungas, Sophia

AU - Lo, Serigne

AU - Chalmers, John

AU - Cass, Alan

AU - Neal, Bruce

AU - Woodward, Mark

AU - Perkovic, Vlado

AU - Glasziou, Paul

AU - Williams, Bryan

AU - Howard, Kirsten

AU - Chapman, Jeremy R.

AU - Craig, Jonathan C.

PY - 2012/8

Y1 - 2012/8

N2 - Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).

AB - Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).

UR - http://www.scopus.com/inward/record.url?scp=84864629526&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfs022

DO - 10.1093/ndt/gfs022

M3 - Article

VL - 27

SP - 3337

EP - 3344

JO - Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress

JF - Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress

SN - 0931-0509

IS - 8

ER -